COMMUNIQUÉS West-GlobeNewswire

Biotech Valuations Rise as New Clinical Platforms Show Progress
24/11/2025
AUSTIN, Texas, Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted Accounting Principles [...]
Imviva Biotech Announces Seven Presentations Highlighting its ANSWER™ Allogeneic CAR-T Platform at the 67th American Society of Hematology Annual Meeting
24/11/2025
Two oral, and five poster presentations will showcase the company’s progress in developing allogenic cell therapy candidates for multiple hematological malignancies CTD402 data for the treatment of T-ALL/LBL selected as [...]
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
24/11/2025
November 24, 2025 Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany is now actively [...]
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
24/11/2025
Study evaluates Lumee™ Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO ₂ ) in peripheral artery disease patients BERKELEY, Calif, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“ [...]
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
24/11/2025
SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces [...]
Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals
24/11/2025
Nanox’s HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease is evaluated PETACH TIKVA, Israel, Nov. 24, 2025 (GLOBE [...]
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
24/11/2025
CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
24/11/2025
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season SAN DIEGO, [...]
HealthLynked Engages NE Holdings, LLC to Lead Strategic Advisory Services for Nasdaq Listing
24/11/2025
NAPLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ), a patient-centric healthcare technology company, announced today that it has entered into a Capital Market Advisory Agreement [...]
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
24/11/2025
PHILADELPHIA, Nov. 24, 2025 (GLOBE NEWSWIRE) -- November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer– especially prostate and [...]
Annovis Announces Two Presentations at the CTAD 2025 Conference
24/11/2025
MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]
ProMIS Neurosciences Announces Reverse Stock Split
24/11/2025
Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other [...]
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
24/11/2025
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures SUNNYVALE, Calif., Nov. 24, [...]
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
24/11/2025
Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- [...]
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
24/11/2025
Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027 Financing anchored by Caligan Partners LP and PBM Capital, along with new and [...]
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
24/11/2025
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
24/11/2025
New findings from Phase 2 adjunctive study evaluating the characteristics of OFF time improvement with solengepras, a novel, non-dopaminergic GPR6 inhibitor; poster selected as one of 10 featured selections for the [...]
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
24/11/2025
REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced [...]
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
24/11/2025
TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with [...]

Pages